PRGS and LOAR reported strong results. Corcept's ROSELLA trial met its primary endpoint, showing relacorilant improved progression-free and overall survival in platinum-resistant ovarian cancer.

Black and American Indian women with ovarian cancer were less likely to have elevated cancer antigen 125 (CA-125) levels at ...

A panelist discusses how National Comprehensive Cancer Network (NCCN) guidelines have influenced molecular testing in ovarian cancer, highlighting the importance of biomarkers like BRCA genes for ...

Dr. Elizabeth K. Lee discusses the RAINFOL-01 clinical trial evaluating treatment with Rina-S in advanced ovarian cancer.

Research has shed light on how a new type of antibody treatment reactivates patients' immune cells to fight ovarian cancer.

Shay Wahl would be the first to tell you that patience isn’t her strong suit. But she’s working on it through her hobbies.

A doctor who specialises in obstetrics and gynaecology described five subtle signs of ovarian cancer everyone should be aware ...

Ovarian cancer affects over 22,000 women annually in the U.S., yet only 20% of cases are caught early. With no reliable ...

AbbVie's Elahere has been shown to reduce the risk of death in patients with folate receptor-alpha (FRα) positive, platinum-resistant ovarian cancer by a third, reinforcing its blockbuster ...

15, 2025 — Bacteria naturally present in the human intestine (known as the gut microbiota) can transform cholesterol-derived bile acids into powerful metabolites that strengthen anti-cancer ...

ovarian cancer progressing under taxane/carboplatin chemotherapy or in early relapse (< 6 months).

A new study led by researchers at Yale University published in Environmental Health Perspectives, suggests that early-life exposure to two widespread environmental pollutants—small particle air ...